JP5954745B2 - ムピロシンの局所用薬学的組成物 - Google Patents

ムピロシンの局所用薬学的組成物 Download PDF

Info

Publication number
JP5954745B2
JP5954745B2 JP2013534305A JP2013534305A JP5954745B2 JP 5954745 B2 JP5954745 B2 JP 5954745B2 JP 2013534305 A JP2013534305 A JP 2013534305A JP 2013534305 A JP2013534305 A JP 2013534305A JP 5954745 B2 JP5954745 B2 JP 5954745B2
Authority
JP
Japan
Prior art keywords
pharmaceutical
mupirocin
composition according
composition
veterinary composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013534305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013543518A (ja
JP2013543518A5 (enExample
Inventor
オヘル， カルロス ゴンザレス
オヘル， カルロス ゴンザレス
アッロ， ベアトリス ゴニ
アッロ， ベアトリス ゴニ
フェルナンデス， フィオナ パストール
フェルナンデス， フィオナ パストール
デ ミゲル， カイエターナ ジャルノス
デ ミゲル， カイエターナ ジャルノス
Original Assignee
ラボラトリオス オヘール ファルマ エセ．エレ．
ラボラトリオス オヘール ファルマ エセ．エレ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラボラトリオス オヘール ファルマ エセ．エレ．, ラボラトリオス オヘール ファルマ エセ．エレ． filed Critical ラボラトリオス オヘール ファルマ エセ．エレ．
Publication of JP2013543518A publication Critical patent/JP2013543518A/ja
Publication of JP2013543518A5 publication Critical patent/JP2013543518A5/ja
Application granted granted Critical
Publication of JP5954745B2 publication Critical patent/JP5954745B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013534305A 2010-10-20 2011-10-19 ムピロシンの局所用薬学的組成物 Active JP5954745B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10382274A EP2444067A1 (en) 2010-10-20 2010-10-20 Anhydrous gel comprising mupirocin
EP10382274.8 2010-10-20
PCT/EP2011/068242 WO2012052472A1 (en) 2010-10-20 2011-10-19 Pharmaceutical topical composition of mupirocin

Publications (3)

Publication Number Publication Date
JP2013543518A JP2013543518A (ja) 2013-12-05
JP2013543518A5 JP2013543518A5 (enExample) 2014-12-04
JP5954745B2 true JP5954745B2 (ja) 2016-07-20

Family

ID=44050874

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013534305A Active JP5954745B2 (ja) 2010-10-20 2011-10-19 ムピロシンの局所用薬学的組成物

Country Status (16)

Country Link
US (1) US9205149B2 (enExample)
EP (2) EP2444067A1 (enExample)
JP (1) JP5954745B2 (enExample)
KR (1) KR101776362B1 (enExample)
CN (1) CN103189048B (enExample)
AU (1) AU2011317636B2 (enExample)
BR (1) BR112013009371B1 (enExample)
CA (1) CA2814103C (enExample)
ES (1) ES2531846T3 (enExample)
MX (1) MX2013004394A (enExample)
NZ (1) NZ609655A (enExample)
PL (1) PL2629756T3 (enExample)
PT (1) PT2629756E (enExample)
RU (1) RU2563840C2 (enExample)
WO (1) WO2012052472A1 (enExample)
ZA (1) ZA201302560B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013285409B2 (en) * 2012-07-06 2018-03-15 Leo Pharma A/S A topical composition comprising a film-forming polymer for delivering an active ingredient to skin
EP2742932A1 (en) 2012-12-17 2014-06-18 Laboratorios Ojer Pharma S.L. Gel compositions
WO2016133471A1 (en) 2015-02-20 2016-08-25 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A. Ş. A topical composition comprising mupirocin and dexpanthenol
WO2017030555A1 (en) 2015-08-17 2017-02-23 Bhalani Vinayak T Topical film delivery system
KR101717699B1 (ko) * 2016-02-11 2017-03-17 아이큐어 주식회사 카타플라스마제용 자외선 경화형 하이드로젤 수지, 하이드로젤 및 이를 포함하는 카타플라스마제
WO2020141482A1 (en) * 2019-01-04 2020-07-09 Glenmark Specialty S.A. Pharmaceutical compositions comprising mupirocin
CN110090198B (zh) * 2019-05-09 2020-02-21 哈尔滨乾佰纳生物药业有限公司 一种具有生物粘附性的缓释型口腔溃疡凝胶及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8530796D0 (en) * 1985-12-13 1986-01-22 Beecham Group Plc Pharmaceutical composition
IE59628B1 (en) 1986-06-26 1994-03-09 Beecham Group Plc Treatment of fungal infections
GB8615669D0 (en) * 1986-06-26 1986-07-30 Beecham Group Plc Treatment
GB9321876D0 (en) * 1993-10-22 1993-12-15 Smithkline Beecham Corp Novel composition
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
EP1033969A1 (en) * 1997-09-11 2000-09-13 Smithkline Beecham Plc Compositions adapted for prolonged residence in the nasal pharynx
IL137363A (en) 2000-07-18 2005-12-18 Agis Ind 1983 Ltd Pharmaceutical compositions containing mupirocin
AU2002950506A0 (en) 2002-07-31 2002-09-12 Soltec Research Pty Ltd Percutaneous delivery system
US7820145B2 (en) * 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8486374B2 (en) * 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US20050123575A1 (en) * 2003-12-03 2005-06-09 Eilon Asculai Spreadable compositions for topical use, an improved process of making same and methods of using same
KR20070080823A (ko) * 2007-01-31 2007-08-13 주식회사 티디에스팜 활성약물 함유 상처 치료용 하이드로겔 제제

Also Published As

Publication number Publication date
KR20130124504A (ko) 2013-11-14
EP2629756B1 (en) 2014-12-24
US9205149B2 (en) 2015-12-08
JP2013543518A (ja) 2013-12-05
CA2814103C (en) 2018-06-12
PT2629756E (pt) 2015-05-21
EP2629756A1 (en) 2013-08-28
MX2013004394A (es) 2013-08-21
RU2013122845A (ru) 2014-11-27
BR112013009371A2 (pt) 2016-07-26
BR112013009371B1 (pt) 2019-08-27
ES2531846T3 (es) 2015-03-20
WO2012052472A1 (en) 2012-04-26
CA2814103A1 (en) 2012-04-26
PL2629756T3 (pl) 2015-06-30
AU2011317636B2 (en) 2016-05-12
NZ609655A (en) 2014-08-29
CN103189048A (zh) 2013-07-03
ZA201302560B (en) 2014-06-25
CN103189048B (zh) 2014-11-26
AU2011317636A1 (en) 2013-05-23
EP2444067A1 (en) 2012-04-25
RU2563840C2 (ru) 2015-09-20
KR101776362B1 (ko) 2017-09-07
US20130267587A1 (en) 2013-10-10

Similar Documents

Publication Publication Date Title
JP5954745B2 (ja) ムピロシンの局所用薬学的組成物
Nasr et al. Formulation and evaluation of cubosomes containing colchicine for transdermal delivery
RU2639591C2 (ru) Тетрациклиновые композиции для местного применения, их получение и применение
CN111065415A (zh) 药剂局部递送的平台及其配制方法
US20110092438A1 (en) Composition for external application comprising transcription factor decoy as active ingredient
US11266600B2 (en) Emulsions for the topical treatment of dermal and mucosal infections
Yılmaz Usta et al. Evaluation of emulgel and nanostructured lipid carrier-based gel formulations for transdermal administration of ibuprofen: Characterization, mechanical properties, and ex-vivo skin permeation
Raju et al. Formulation and evaluation of ornidazole topical emulgel
Al-Sakini et al. In vitro evaluation of the effect of using different gelling agents on the release of erythromycin from a nanocubosomal gel
JP2020526512A (ja) 新規のセクニダゾールの軟ゼラチンカプセル製剤及びその使用
Anwer et al. Punica granatum Loaded Glycerosomes for Antibacterial Effect in Skin Infections: Preparation, Optimization, In Vitro and In Vivo Characterization
Dandagi et al. Formulation and evaluation of linezolid niosomal gel for topical drug delivery
Ed-Drourh Justification of the composition of a soft medicinal product for the treatment of herpes infection
RU2804658C2 (ru) Суспензионные композиции высоконцентрированных дисперсий
ES2387440B2 (es) Formulaciones topicas de anfotericina b y metodo de obtencion
Mehmood et al. Development of nanospray loaded with ciclopirox for dermal fungus treatment: determination of pro-inflammatory interleukin IL-2 mRNA expression
RU2498806C2 (ru) Фармацевтический состав для лечения инфекционных воспалительных заболеваний в гинекологии и способ его получения
CN120981221A (zh) 用于局部施用的组合物
BR102018073592B1 (pt) Processo de obtenção de nanocarreadores lipídicos à base de manteiga de karité e óleo de argan modificados com polímeros bioadesivos, nanocarreadores lipídicos à base de manteiga de karité e óleo de argan modificados com polímeros bioadesivos e uso dos nanocarreadores lipídicos
EA041079B1 (ru) Эмульсия для местного лечения инфекций кожи и слизистых оболочек
Bhanajibhai Formulation and Evaluation of PANCHATIKTA-As a Semisolid Dosage Form for Its Wound Healing Property
Patel Preparation and Evaluation of Topical Preparation of Norfloxacin
Shah Preparation and Characterization Transdermal Film Of Valsartan

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141017

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160510

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160607

R150 Certificate of patent or registration of utility model

Ref document number: 5954745

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250